Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on‐demand with bypass treatment-Reference-Cited by-同舟云学术

Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on‐demand with bypass treatment

Published:2015-02-16 Issue:3 Volume:21 Page:310-319
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Earnshaw S. R.¹,Graham C. N.¹,McDade C. L.¹,Spears J. B.²,Kessler C. M.³

Affiliation:

1. RTI Health Solutions Research Triangle ParkNC USA

2. Grifols, Inc. Research Commons NCUSA

3. Georgetown University Medical Center Washington DC USA

Funder

Grifols Therapeutics Inc

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.12621

Reference37 articles.

1. Haemophilias A and B

2. Guidelines for the management of hemophilia

3. World Federation of Hemophilia.Guidelines for the management of hemophilia.2ndedition.2012. Available at:http://www1.wfh.org/publications/files/pdf-1472.pdf. Accessed October 20 2014.

4. How we treat a hemophilia A patient with a factor VIII inhibitor

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing health plan payer’s budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States;Journal of Managed Care & Specialty Pharmacy;2024-08

2. Gene Therapy in Hemophilia A: Achievements, Challenges, and Perspectives;Seminars in Thrombosis and Hemostasis;2024-04-08

3. Race and ethnicity and the success of immune tolerance induction among people with severe haemophilia A in the United States;Haemophilia;2024-03-10

4. Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A;Blood Reviews;2023-12

5. Emicizumab: the hemophilia A game changer;Haematologica;2023-11-02